Table V.3: The Number of States That Reported Having Entered into a Long-Term Drug Compounding Information Sharing Agreement with FDA, and How These States Rated the Effectiveness of the Agreement for Sharing Information Regarding Drug Compounding | |||||||||
---|---|---|---|---|---|---|---|---|---|
Number of states (%) | How states that reported having a 20.88 agreement rated the effectiveness of this agreement for sharing information regarding drug compounding | ||||||||
Yes, our office has entered into a 20.88 agreement with FDAa | Yes, another state agency, office, or department has entered into a 20.88 agreement with FDAa | No | Don't know | No response | Very or somewhat effective | Neither effective nor ineffective | Somewhat or very ineffective | Don't know | No response |
10 (20) | 1 (2) | 25 (50) | 12 (24) | 2 (4) | 8 | 2 | 0 | 0 | 1 |
Source: GAO survey of state pharmacy regulatory bodies, survey question 31. | GAO-17-363SP |
Notes: GAO surveyed the state pharmacy regulatory bodies in the 50 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands, and all but 4 completed the survey. |
aThe Food and Drug Administration (FDA) can share certain nonpublic information, including confidential commercial information, with state and local officials under a written confidentiality agreement entered into under its regulations at 21 C.F.R 20.88 (referred to as a 20.88 agreement). |